-
Electronic (PDF)
-
Site License
-
Enterprisewide
Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, August 2011, Pages: 93
Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Post Menopausal Osteoporosis Therapeutics market. The report identifies the key trends shaping and driving the global Post Menopausal Osteoporosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post Menopausal Osteoporosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Post Menopausal Osteoporosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post Menopausal Osteoporosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Post Menopausal Osteoporosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post Menopausal Osteoporosis Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Post Menopausal Osteoporosis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Post Menopausal Osteoporosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post Menopausal Osteoporosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Post Menopausal Osteoporosis Therapeutics market landscape? – Identify, understand and capitalize.
1
1
1.1 List of Tables
1.2 List of Figures
2 Postmenopausal Osteoporosis Therapeutics: Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Diagnosis
2.6.1 Medical History
2.6.2 BMD Testing
2.6.3 Laboratory Tests
2.7 Treatment and Management Options
2.8 Pipeline Report Guidance
3 Postmenopausal Osteoporosis Therapeutics: Market Characterization
3.1 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – Global
3.2 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – Global
3.3 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – The US
3.4 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – The US
3.5 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – France
3.6 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – France
3.7 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – Germany
3.8 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – Germany
3.9 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – Italy
3.10 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – Italy
3.11 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – Spain
3.12 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – Spain
3.13 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – The UK
3.14 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – The UK
3.15 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) – Japan
3.16 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the Postmenopausal Osteoporosis Therapeutics Market
3.17.1 Drivers for the Postmenopausal Osteoporosis Therapeutics Market
3.17.2 Barriers for the Postmenopausal Osteoporosis Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Postmenopausal Osteoporosis Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Postmenopausal Osteoporosis Therapeutics Market
4.3.1 Fosamax (alendronate sodium)
4.3.2 Actonel (risedronate sodium)
4.3.3 Boniva (ibandronate sodium)
4.3.4 Reclast (zoledronic acid)
4.3.5 Evista (raloxifene hydrochloride)
4.3.6 Prolia (denosumab)
4.3.7 Forteo (teriparatide [rDNA origin]) injection
4.3.8 Miacalcin (salmon calcitonin)
4.3.9 Activella (estradiol, norethindrone acetate)
4.3.10 Premarin (estrogen)
4.3.11 Prempro (conjugated estrogens and medroxyprogesterone acetate)
4.4 Key Takeaway
5 Postmenopausal Osteoporosis Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Postmenopausal Osteoporosis Therapeutics – Pipeline by Phases of Development
5.3.1 Postmenopausal Osteoporosis Therapeutics – Phase III Pipeline
5.3.2 Postmenopausal Osteoporosis Therapeutics – Phase II Pipeline
5.3.3 Postmenopausal Osteoporosis Therapeutics – Phase I Pipeline
5.3.4 Postmenopausal Osteoporosis Market – Pre-Clinical Pipeline
5.3.5 Technology Trends Analytic Framework
5.4 Postmenopausal Osteoporosis Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 Postmenopausal Osteoporosis Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 Odanacatib (MK-0822)
5.6.2 PREOS (parathyroid hormone 1-84 [rDNA origin] injection)
5.6.3 NB S101
5.6.4 SMC021
5.7 Key Takeaway
6 Postmenopausal Osteoporosis Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Clinical Trials by Overall Sponsors
6.6 Top Companies Participating in Postmenopausal Osteoporosis Therapeutics Clinical Trials
7 Postmenopausal Osteoporosis Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Postmenopausal Osteoporosis Therapeutics: Implications for Future Market Competition
8 Postmenopausal Osteoporosis Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Amgen Inc.
8.2.2 Merck & Co., Inc.
8.2.3 Novartis AG
8.2.4 NPS Pharmaceuticals
8.2.5 Osteologix, Inc.
8.2.6 Other Companies in the Postmenopausal Osteoporosis Market
9 Postmenopausal Osteoporosis Therapeutics: Licensing & Partnership Deals
10 Postmenopausal Osteoporosis Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Difference Between Type I and Type II Osteoporosis
Table 2: Osteoporosis Prevalence and Low Bone Mass in People Aged 50 and Over (The US) (million)-
Table 3: Difference Between Diagnostic Techniques Used for BMD Measurement
Table 4: WHO Classification for Diagnosis of Osteoporosis Using BMD Measurements
Table 5: Approved Drugs for the Prevention and Treatment of Postmenopausal Osteoporosis
Table 6: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 7: Postmenopausal Osteoporosis Therapeutics Market, Global, Forecast ($bn), 2010–2017
Table 8: Postmenopausal Osteoporosis Therapeutics Market, The US, Revenue ($bn), 2005–2010
Table 9: Postmenopausal Osteoporosis Therapeutics Market, The US, Forecast ($bn), 2010–2017
Table 10: Postmenopausal Osteoporosis Therapeutics Market, France, Revenue ($m), 2005–2010
Table 11: Postmenopausal Osteoporosis Therapeutics Market, France, Forecast ($m), 2010–2017
Table 12: Postmenopausal Osteoporosis Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 13: Postmenopausal Osteoporosis Therapeutics Market, Germany, Forecast ($m), 2010–2017
Table 14: Postmenopausal Osteoporosis Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 15: Postmenopausal Osteoporosis Therapeutics Market, Italy, Forecast ($m), 2010–2017
Table 16: Postmenopausal Osteoporosis Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 17: Postmenopausal Osteoporosis Therapeutics Market, Spain, Forecast ($m), 2010–2017
Table 18: Postmenopausal Osteoporosis Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 19: Postmenopausal Osteoporosis Therapeutics Market, The UK, Forecast ($m), 2010–2017
Table 20: Postmenopausal Osteoporosis Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 21: Postmenopausal Osteoporosis Therapeutics Market, Japan, Forecast ($m), 2010–2017
Table 22: Effect of Actonel on the Risk of Vertebral Fractures
Table 23: Effect of Evista on Risk of Vertebral Fractures
Table 24: Effect of Evista on Increases in BMD vs. Placebo
Table 25: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis
Table 26: Mean Percentage Change in BMD in Postmenopausal Women with Osteoporosis
Table 27: Postmenopausal Osteoporosis Therapeutics – Phase III Pipeline, 2010
Table 28: Postmenopausal Osteoporosis Therapeutics – Phase II Pipeline, 2010
Table 29: Postmenopausal Osteoporosis Therapeutics – Phase I Pipeline, 2010
Table 30: Postmenopausal Osteoporosis Therapeutics – Pre-Clinical Pipeline, 2010
Table 31: Postmenopausal Osteoporosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 32: Postmenopausal Osteoporosis Therapeutics Market – Clinical Trials by Region/ Country, 2010
Table 33: Postmenopausal Osteoporosis Therapeutics – Clinical Trials by Phase, 2010
Table 34: Postmenopausal Osteoporosis Therapeutics – Clinical Trials by Status, 2010
Table 35: Postmenopausal Osteoporosis Therapeutics –Prominent Sponsors, 2010
Table 36: Postmenopausal Osteoporosis Therapeutics – Overall Sponsors, 2010
Table 37: Postmenopausal Osteoporosis Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2010
Table 38: Amgen Inc. – Deals, Alliances and Partnership
Table 39: Merck & Co., Inc. – Deals, Alliances and Partnership
Table 40: Merck & Co., Inc. – Women’s Health Pipeline, 2010
Table 41: Novartis AG – Deals, Alliances and Partnership
Table 42: Novartis AG - Women’s Health Pipeline Products, 2010
Table 43: NPS Pharmaceuticals – Deals, Alliances and Partnership
Table 44: NPS Pharmaceuticals – Women’s Health Pipeline, 2010
Table 45: Osteologix, Inc. – Deals, Alliances and Partnership
Table 46: Osteologix, Inc. – Women’s Health Pipeline, 2010
Table 47: Postmenopausal Osteoporosis Therapeutics Market – Future Players
Table 48: Postmenopausal Osteoporosis Therapeutics, Global, Deals
1.2 List of Figures
Figure 1: Variation in the Levels of Bone Density with Age in Females
Figure 2: Classification of Osteoporosis
Figure 3: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2005–2010
Figure 4: Postmenopausal Osteoporosis Therapeutics Market, Global, Forecast ($bn), 2010–2017
Figure 5: Postmenopausal Osteoporosis Therapeutics Market, The US, Revenue ($bn), 2005–2010
Figure 6: Postmenopausal Osteoporosis Therapeutics Market, The US, Forecast ($bn), 2010–2017
Figure 7: Postmenopausal Osteoporosis Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 8: Postmenopausal Osteoporosis Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 9: Postmenopausal Osteoporosis Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 10: Postmenopausal Osteoporosis Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 11: Postmenopausal Osteoporosis Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 12: Postmenopausal Osteoporosis Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 13: Postmenopausal Osteoporosis Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 14: Postmenopausal Osteoporosis Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 15: Postmenopausal Osteoporosis Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 16: Postmenopausal Osteoporosis Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 17: Postmenopausal Osteoporosis Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 18: Postmenopausal Osteoporosis Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 19: Opportunity and Unmet Need in the Postmenopausal Osteoporosis Therapeutics Market
Figure 20: Postmenopausal Osteoporosis Therapeutics – Strategic Competitor Assessment, 2010
Figure 21: Postmenopausal Osteoporosis Therapeutics – Pipeline by Phase of Development, 2010
Figure 22: Postmenopausal Osteoporosis Therapeutics – Technology Trends Analytics Framework, 2010
Figure 23: Postmenopausal Osteoporosis Therapeutics – Technology Trends Analytics Framework – Description, 2010
Figure 24: Postmenopausal Osteoporosis Therapeutics – Pipeline by Mechanism of Action, 2010
Figure 25: Postmenopausal Osteoporosis Therapeutics – Clinical Trials by Country, 2010
Figure 26: Postmenopausal Osteoporosis Therapeutics – Clinical Trials by Phase, 2010
Figure 27: Postmenopausal Osteoporosis Therapeutics – Clinical Trials by Status, 2010
Figure 28: Postmenopausal Osteoporosis Therapeutics –Prominent Sponsors, 2010
Figure 29: Postmenopausal Osteoporosis Therapeutics – Overall Sponsors, 2010
Figure 30: Postmenopausal Osteoporosis Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2010
Figure 31: Postmenopausal Osteoporosis Therapeutics Market – Drivers and Restraints 2010
Figure 32: Implications for Future Market Competition in the Postmenopausal Osteoporosis Market, 2010
Figure 33: Postmenopausal Osteoporosis Therapeutics Market – Pipeline by Company, 2010
Figure 34: Market Forecasting Model
Amgen Inc.
Merck & Co., Inc.
Novartis AG
NPS Pharmaceuticals
Osteologix, Inc.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
